Crinetics PharmaceuticalsCRNX
CRNX
About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Employees: 210
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 72
15% more capital invested
Capital invested by funds: $3.78B [Q2] → $4.34B (+$552M) [Q3]
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0% less funds holding
Funds holding: 233 [Q2] → 232 (-1) [Q3]
1.2% less ownership
Funds ownership: 107.13% [Q2] → 105.93% (-1.2%) [Q3]
8% less funds holding in top 10
Funds holding in top 10: 13 [Q2] → 12 (-1) [Q3]
30% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $2.28M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$74
98%
upside
Avg. target
$81
116%
upside
High target
$87
133%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 56 / 172 met price target | 117%upside $81 | Buy Reiterated | 13 Jan 2025 |
JMP Securities Jonathan Wolleben 29% 1-year accuracy 22 / 75 met price target | 133%upside $87 | Market Outperform Reiterated | 16 Dec 2024 |
Citigroup David Lebovitz 65% 1-year accuracy 11 / 17 met price target | 98%upside $74 | Buy Maintained | 14 Nov 2024 |
Financial journalist opinion
Based on 4 articles about CRNX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 week ago
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione
Neutral
GlobeNewsWire
2 weeks ago
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time.
Positive
Seeking Alpha
2 weeks ago
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement.
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025
Neutral
GlobeNewsWire
2 months ago
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Neutral
Seeking Alpha
2 months ago
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Marc Wilson - Chief Financial Officer Dana Pizzuti - Chief Medical and Development Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Cory Jubinville - LifeSci Capital Jessica Fye - J.P. Morgan Jeff Hung - Morgan Stanley Charlie Moore - Baird Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Douglas Tsao - H.C.
Neutral
GlobeNewsWire
2 months ago
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Neutral
GlobeNewsWire
2 months ago
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine Tumor Society (NANETS) Total of Four New Drug Candidates in IND-Enabling Preclinical Studies Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the third quarter ended September 30, 2024.
Charts implemented using Lightweight Charts™